Welcome to our dedicated page for Vycor Med SEC filings (Ticker: VYCO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The VYCO SEC filings page on Stock Titan provides access to regulatory documents filed by Vycor Medical, Inc. with the U.S. Securities and Exchange Commission. Vycor Medical, Inc. is a Delaware corporation that reports under Commission File Number 001-34932, as indicated in its Form 8-K. These filings give investors and researchers insight into the company’s financial reporting and disclosure practices.
One example is the Form 8-K dated November 14, 2025, in which Vycor Medical, Inc. furnished information under Item 2.02 – Results of Operations and Financial Condition. That filing references a press release, attached as Exhibit 99.1, discussing financial results for the three and nine months ended September 30, 2025. The company also identifies Exhibit 104 as the cover page interactive data file embedded within the Inline XBRL document.
In this Form 8-K, Vycor Medical, Inc. explains that it uses non-GAAP financial measures such as non-GAAP Cash Operating Expenses and non-GAAP Cash Operating Loss, which exclude depreciation and non-cash stock compensation from the comparable GAAP measures. The company notes that reconciliations of these non-GAAP figures to GAAP are included in the press release exhibit, and that such measures are intended to help management compare ongoing operating results and trends.
On Stock Titan, users can review Vycor Medical, Inc.’s historical and current SEC filings, including Forms 8-K and their exhibits, to understand how the company reports its results and describes its financial condition. AI-powered tools on the platform can help summarize key points from lengthy filings, highlight important items such as non-GAAP reconciliations, and make it easier to interpret structured data elements like Inline XBRL cover page information.
Vycor Medical, Inc. reported 2025 revenue of $1,863,400, up 17% from 2024, driven mainly by international growth in its Vycor Medical (VBAS) neurosurgery business. VBAS revenue reached $1,796,070, an 18% increase, while NovaVision contributed $67,330.
Gross profit rose to $1,561,107 with an 83% margin, down from 89% in 2024 due to new production, shipping, and higher international mix. On a GAAP basis, Vycor generated operating income of $33,900 but recorded a net loss available to common stockholders of $396,796, or $0.01 per share, after preferred dividends.
Excluding non-cash depreciation and stock-based compensation, non-GAAP cash operating expenses were $1,415,226 and non-GAAP operating profit improved to $145,881. Non-GAAP net loss available to common shareholders narrowed to $284,815, or $0.01 per share, indicating better underlying operating performance despite continued net losses.
Vycor Medical, Inc. reports full-year 2025 results and highlights significant going concern risks. Total revenue reached $1,863,400, up from 2024, driven mainly by Vycor Medical product sales of $1,796,070, an 18% increase. Consolidated gross profit was $1,561,107, with Vycor Medical posting an 83% gross margin and NovaVision 93%.
The company recorded a modest net loss of $72,426, but after $324,370 of cumulative preferred dividends on Series D stock, net loss available to common stockholders was $396,796. Cash was only $86,982 at December 31, 2025, against a working capital deficiency of $4,218,046, including $3,658,382 of related-party liabilities. Auditors and management state these factors raise substantial doubt about Vycor’s ability to continue as a going concern.
Vycor Medical, Inc. furnished an Item 2.02 report announcing a press release with financial results for the three and nine months ended September 30, 2025.
The release includes non-GAAP measures—Cash Operating Expenses and Cash Operating Loss—which exclude Depreciation and non-cash Stock Compensation, with reconciliations to comparable GAAP measures. The press release is attached as Exhibit 99.1, and the information is furnished and not deemed “filed” under the Exchange Act.
Vycor Medical (VYCO) filed its quarterly report, highlighting higher sales alongside continued financial pressure. Q3 revenue was $513,792, up 31% year over year, led by Vycor Medical products, with gross profit of $451,932. The company produced operating income of $32,085 versus a prior-year loss, and reported net income of $4,936 before preferred dividends.
After $162,185 in cumulative preferred dividends for the quarter, net loss available to common stockholders was $(157,249). Cash was $64,230 and the working capital deficit was $(4,152,481). Total liabilities stood at $4,965,388 and stockholders’ deficiency at $(4,024,193). Management disclosed substantial doubt about the company’s ability to continue as a going concern.
The filing notes a $300,000 EuroAmerican note (accrued interest $556,932) extended to March 31, 2026 and an SBA EIDL balance of $136,745. There were 33,372,796 common shares outstanding as of November 14, 2025.